Basilea Pharmaceutica AG

OTCPK:BPMU.F Stock Report

Market Cap: US$570.1m

Basilea Pharmaceutica Management

Management criteria checks 4/4

Basilea Pharmaceutica's CEO is David Veitch, appointed in Apr 2018, has a tenure of 6.75 years. total yearly compensation is CHF1.75M, comprised of 35% salary and 65% bonuses, including company stock and options. directly owns 0.011% of the company’s shares, worth $61.17K. The average tenure of the management team and the board of directors is 7 years and 9.8 years respectively.

Key information

David Veitch

Chief executive officer

CHF 1.7m

Total compensation

CEO salary percentage35.0%
CEO tenure6.8yrs
CEO ownership0.01%
Management average tenure7yrs
Board average tenure9.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has David Veitch's remuneration changed compared to Basilea Pharmaceutica's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CHF 652k

Mar 31 2024n/an/a

CHF 5m

Dec 31 2023CHF 2mCHF 611k

CHF 10m

Sep 30 2023n/an/a

CHF 33m

Jun 30 2023n/an/a

CHF 56m

Mar 31 2023n/an/a

CHF 34m

Dec 31 2022CHF 2mCHF 599k

CHF 12m

Sep 30 2022n/an/a

CHF 6m

Jun 30 2022n/an/a

CHF 851k

Mar 31 2022n/an/a

-CHF 3m

Dec 31 2021CHF 2mCHF 594k

-CHF 7m

Sep 30 2021n/an/a

-CHF 26m

Jun 30 2021n/an/a

-CHF 45m

Mar 31 2021n/an/a

-CHF 30m

Dec 31 2020CHF 1mCHF 589k

-CHF 15m

Sep 30 2020n/an/a

-CHF 6m

Jun 30 2020n/an/a

CHF 3m

Mar 31 2020n/an/a

-CHF 10m

Dec 31 2019CHF 1mCHF 583k

-CHF 22m

Sep 30 2019n/an/a

-CHF 23m

Jun 30 2019n/an/a

-CHF 24m

Mar 31 2019n/an/a

-CHF 28m

Dec 31 2018CHF 2mCHF 529k

-CHF 31m

Compensation vs Market: David's total compensation ($USD1.92M) is about average for companies of similar size in the US market ($USD2.26M).

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.

CEO

David Veitch (59 yo)

6.8yrs

Tenure

CHF 1,745,679

Compensation

Mr. David Veitch has been the Chief Executive Officer of Basilea Pharmaceutica Ltd. since April 19, 2018 and Basilea Pharmaceutica International Ltd., since September 1, 2014. Mr. Veitch joined Basilea in...

Leadership Team

NamePositionTenureCompensationOwnership
David Veitch
Chief Executive Officer6.8yrsCHF 1.75m0.011%
$ 61.2k
Adesh Kaul
Chief Financial Officer5.8yrsno data0.0041%
$ 23.5k
Gerrit Hauck
Chief Technology Officer6.7yrsno datano data
Laurenz Kellenberger
Chief Scientific Officer16yrsno data0.0041%
$ 23.5k
Marc Engelhardt
Chief Medical Officer7yrsno datano data
Peer Schroder
Head of Corporate Communications & Investor Relationsno datano datano data
Damian Heller
General Counsel & Corporate Secretary7.4yrsno datano data
Andreas Kumin
Head of Corporate Developmentno datano datano data
Ursula Eberhardt
Head of Global Human Resources8yrsno datano data
Mark Jones
Head of Global Affairs7yrsno datano data
Peter Bielmeier
Head of Global Quality Management2.3yrsno datano data
Mohammed Benghezal
Head of Biologyno datano datano data

7.0yrs

Average Tenure

58yo

Average Age

Experienced Management: BPMU.F's management team is seasoned and experienced (7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Nicole Onetto
Independent Non-Executive Director7.8yrsCHF 192.13k0.0061%
$ 34.7k
Leonard Kruimer
Independent Non-Executive Director2.8yrsCHF 186.88kno data
Domenico Scala
Independent Chairman of the Board13.2yrsCHF 337.68k0.0049%
$ 27.8k
Alf Gunnar Nicklasson
Independent Non-Executive Director11.8yrsCHF 211.75k0.015%
$ 82.7k
Carole Sable
Independent Non-Executive Director1.8yrsCHF 192.13kno data
Thomas Werner
Independent Vice-Chairman13.2yrsCHF 224.80k0.0098%
$ 56.0k

9.8yrs

Average Tenure

67yo

Average Age

Experienced Board: BPMU.F's board of directors are considered experienced (9.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 06:56
End of Day Share Price 2024/10/11 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Basilea Pharmaceutica AG is covered by 25 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Leonildo DelgadoBaader Helvea Equity Research
Volker BosseBaader Helvea Equity Research
Markus MayerBaader Helvea Equity Research